The decline happened because the loss of Rs 2277 crore that the company posted in the March 2022 quarter. This loss happened because of the one-time charge that the company incurred due to payment for legal settlements in United States. Most of this payment was for settling a class- action suit brought against Ranbaxy in United States. Ranbaxy is now a subsidiary of Sun Pharma after the latter acquired it. The class action suit brought by some US citizens alleged that Ranbaxy did fraud to delay the launch by competitors of their own generic medicines in the US market.
After the decline today, Sun Pharma’s stock may see some uptick in the coming days on the back of value buying.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.